Amendment of Disclosures in Past Management Information Circulars

Company Overview - BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds BETR-001 and BETR-002 for neuro-psychiatric and neurological disorders [6] - BETR-001 is a non-hallucinogenic derivative of LSD, currently in preclinical and IND-enabling studies, and is unique as it is unregulated and can be self-administered [2][4] - BETR-002, also in preclinical and IND-enabling studies, is based on honokiol, aimed at treating anxiety-related disorders including benzodiazepine dependency [7] Recent Developments - The company has issued 350,000 common shares and 350,000 share purchase warrants due to the conversion of convertible debentures totaling $35,000, with warrants exercisable at$0.10 per share until August 31, 2026 [5] - A review by the British Columbia Securities Commission prompted BetterLife to clarify disclosures regarding beneficial ownership by its CEO, Dr. Ahmad Doroudian [4] Intellectual Property - BetterLife holds a synthesis patent for BETR-001 that eliminates regulatory hurdles, and a pending patent covering treatment methods for major depressive disorder, anxiety disorder, and neuropathic pain [2]